You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
億勝生物科技(01061.HK)與特許人復宏漢霖-B(02696.HK)訂立共同開發許可協議
格隆匯 10-15 17:20

格隆匯 10 月 15日丨億勝生物科技(01061.HK)宣佈,於2020年10月15日,受許人(均為公司的全資附屬公司)與特許人復宏漢霖-B(02696.HK)訂立共同開發許可協議,據此,(i)受許人同意共同出資開發許可產品;及(ii)受許人獲授許可知識產權項下之許可,(a)就有關許可產品的任何目的使用及查閲檔案資料;及(b)於該地域內該領域的許可產品之監管發展、製造及按受許人的一個或多個商標商業化,該許可為可轉授、永久及不可撤回、可轉讓及獨家性質,惟受限於共同開發許可協議的條款。

根據共同開發許可協議,受許人須向特許人支付簽署付款、後續監管里程碑付款及分擔開發成本合共最多4900萬美元及(如適用)商業銷售里程碑付款及╱或特許權使用費(均按許可產品於該地域的淨銷售額徵收)。

據悉,特許人為一家集團的控股公司,該集團主要從事(i)單克隆抗體(mAb)藥物的研發、生產及銷售以及提供相關技術服務(除人體幹細胞、基因診斷及治療技術的開發及應用);及(ii)轉讓其自有技術及提供相關技術諮詢服務。

化合物("HLX04-o-wAMD")目前是一種貝伐珠單抗生物仿製候選藥物。貝伐珠單抗已獲批准為癌症治療藥,但由醫生用於眼科治療。許可產品將包含化合物作為活性藥物成分,擬用於治療滲出性(濕性)老年性黃斑部病變。董事認為,共同開發許可協議為各訂約方發揮彼等各自之優勢及資源,共同致力於及加快全球市場眼科產品之開發提供良機。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account